CAL-101 High Purity PI3K Delta Inhibitor Research Compound
TDS
870281-82-6
Pharmaceutical Grade
99%
深圳
OEM
cal-101
2026-08-28
Retatrutide,Tirzepatide,Semaglutide,GHK-CU,NAD+,MOTS-C
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceIdelalisib (CAL-101) is a highly selective and potent p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
Idelalisib is a member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia. It has a role as an antineoplastic agent, an apoptosis inducer and an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor. It is a member of purines, an organofluorine compound, a member of quinazolines, an aromatic amine and a secondary amino compound.|Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.|Idelalisib is a Kinase Inhibitor. The mechanism of action of idelalisib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor.|Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular B cell and small lymphocytic lymphoma. Idelalisib is associated with a high rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal.|Idelalisib is an orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.Certificates-
TDS
Basic Info-
Product Name:
Idelalisib
Other Name:4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-;4(3H)-Quinazolinone,5-fluoro-3-phenyl-2-[(1S)-1-(1H-purin-6-ylamino)propyl]-;5-Fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone;CAL 101;GS 1101;Idelalisib;Zydelig;N6-[(S)-1-(5-Fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl]adenine;Delalisib;(S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
CAS No.:870281-82-6
Molecular Formula:C22H18FN7O
InChIKeys:InChIKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N
Molecular Weight:415.4230232
Exact Mass:415.42
UNII:YG57I8T5M0
NCI Thesaurus Code:C78825
Color/Form:White to off-white powder
ATC Code:L01XX47|L - Antineoplastic and immunomodulating agents
HScode:29399990
Categories:
Characteristics-
PSA:
99.2
XLogP3:3.7
Density:1.47
Refractive Index:1.741
Water Solubility:In water, 1.19 mg/L at 25 °C (est)|pH-dependent solubility ranging from <0.1 mg/mL at pH 5-7 to over 1 mg/mL at pH 2 under ambient conditions
Storage Conditions:Keep container tightly closed. Store in accordance with information listed on the product insert.|Store between 20-30 °C (68-86 °F) with excursions permitted 15-30 °C (59-86 °F).
Vapor Pressure:5.2X10-16 mm Hg at 25 °C (est)
Henrys Law Constant:Henry's Law constant = 1.07X10-20 atm-cu m/mol at 25 °C (est)
Experimental Properties:Hydroxyl radical reaction rate constant = 2.42X10-10 cu cm/molec-sec at 25 °C (est)
Hazard IdentificationClassification of the substance or mixture
Specific target organ toxicity â repeated exposure, Category 1
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H372 Causes damage to organs through prolonged or repeated exposure
Precautionary statement(s) Prevention P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response P319 Get medical help if you feel unwell.
Storage none
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Retatrutide,Tirzepatide,Semaglutide,GHK-CU,NAD+,MOTS-C
-
Location:
Block 1, No. 205, Tongbao Road, Jiangdong Street, Yiwu City, Jinhua City, Zhejiang Province (within Zhejiang Juzhiyun Holding Co., Ltd., on the 4th floor of 2 buildings)
-
Payment Terms:
TT against copy of documents,O/A,100% TT in advance
-
Total Employees:
101-200
-
Year of Establishment:
2026
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
Hot Related Products
-
![Solvent Blue 101]( "Solvent Blue 101")
Solvent Blue 101$0.1/KG EXW
-
![1,4-bis[(2-methylphenyl)amino]anthraquinone]( "1,4-bis[(2-methylphenyl)amino]anthraquinone")
1,4-bis[(2-methylphenyl)amino]anthraquinone -
![Solvent Blue 101]( "Solvent Blue 101")
Solvent Blue 101 -
![1,4-bis(2-methylanilino)anthracene-9,10-dione]( "1,4-bis(2-methylanilino)anthracene-9,10-dione")
1,4-bis(2-methylanilino)anthracene-9,10-dione -
![1,4-bis[(2-methylphenyl)amino]anthraquinone]( "1,4-bis[(2-methylphenyl)amino]anthraquinone")
1,4-bis[(2-methylphenyl)amino]anthraquinone -
![1,4-bis[(2-methylphenyl)amino]anthraquinone]( "1,4-bis[(2-methylphenyl)amino]anthraquinone")
1,4-bis[(2-methylphenyl)amino]anthraquinone -
![SULFORHODAMINE 101 ACID CHLORIDE]( "SULFORHODAMINE 101 ACID CHLORIDE")
SULFORHODAMINE 101 ACID CHLORIDE -
![SULFORHODAMINE 101 ACID CHLORIDE]( "SULFORHODAMINE 101 ACID CHLORIDE")
SULFORHODAMINE 101 ACID CHLORIDE -
![Texas red]( "Texas red")
Texas red -
![SULFORHODAMINE101ACIDCHLORIDE]( "SULFORHODAMINE101ACIDCHLORIDE")
SULFORHODAMINE101ACIDCHLORIDE
![1,4-bis[(2-methylphenyl)amino]anthraquinone](https://file.echemi.com/fileManage/upload/canonicalSmiles/20220812/8bf4e381d082445a9a50c975d756f0cf.png "1,4-bis[(2-methylphenyl)amino]anthraquinone")
